Skip to main content

Targeting Transcription Factor Activity as a Strategy to Inhibit Pro- Inflammatory Genes Involved in Cystic Fibrosis: Decoy Oligonucleotides and Low-Molecular Weight Compounds

Buy Article:

$55.00 plus tax (Refund Policy)

The development of drugs able to inhibit the expression of pro-inflammatory genes is of great interest in the treatment of cystic fibrosis (CF). Chronic pulmonary inflammation in the lungs of patients affected by CF is characterized by massive intra-bronchial infiltrates of neutrophils. This process is initiated upon interaction of pathogens (including Pseudomonas aeruginosa) with surface bronchial cells. Consequently, they release cytokines, the most represented being the potent neutrophilic chemokine Interleukin (IL)-8 and the pro-inflammatory cytokine IL-6. The chronic inflammatory process is crucial, since it leads to progressive tissue damage and severe respiratory insufficiency.

In order to reduce the adverse effects of the excessive inflammatory response, one of the approaches leading to inhibition of IL-8 and IL-6 gene expression is the transcription factor (TF) decoy approach, based on intracellular delivery of double stranded oligodeoxynucleotides (ODNs) mimicking the binding sites of TFs and causing inhibition of binding of TFrelated proteins to regulatory sequences identified in the promoters of specific genes. Since the promoters of IL-8 and IL-6 contain consensus sequences for NF-κB and Sp1, double stranded TF “decoy” ODNs targeting NF-κB and Sp1 can be used.

Alternatively, screening of drugs targeting relevant TFs can be performed using drug cocktails constituted by extracts from medicinal plants inhibiting TF/DNA interactions.

Finally, virtual screening might lead to identification of putative bioactive molecules to be validated using molecular and cellular approaches. By these means, low-molecular drugs targeting NF-κB and inhibiting IL-8 gene expression are available for pre-clinical testing using experimental systems recapitulating chronic pulmonary inflammation of patients affected by CF.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: (IL)-8; (TGF); APCs; ASL; ATA; BALF; Bronchial Epithelial Cells; CF; CFTR; CFTR protein; CXCR1; Cystic fibrosis; EMSA; ENaC; H. influenzae; HIV-1 LTR NF-B; HPLC; Helicobacter pylori; IB3 cells; IB3-1; ICAM-1; IL-1; IL-6; IL-8; LL-37; NET; NF-B; ODNs; P.aeruginosa; PAO1; PMN; PMNs; PNAs; Pseudomonas aeruginosa; ROS; Resveratrol; S. aureus; Sp1; T lymphocytes; TF; TFD; TFs; TLR; VS; acidification; adhesion molecule ICAM-1; cDNA; chemokines; cytokines; decoy; inflammation; inflammatory disease; leukocytes; phages; toxins; transcription factors

Document Type: Research Article

Publication date: 2010-12-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more